Talabostat. Oncolytic hematopoietic agent dipeptidyl-peptidase IV (CD26) inhibitor fibroblast activation protein inhibitor

Drugs of the Future

Volumn 29, Issue 9, 2004, Pages 882-886

  McIntyre, J A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BETA INTERFERON; CELL PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN; DIPEPTIDYL PEPTIDASE; DOCETAXEL; FIBROBLAST ACTIVATOR PROTEIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HELPER CELL PEPTIDE; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN; PACLITAXEL; RITUXIMAB; SERINE PROTEINASE INHIBITOR; TALABOSTAT; UNCLASSIFIED DRUG; VACCINE; VALBOROPRO;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD CELL; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER PATIENT; CELL ACTIVATION; CELL GROWTH; CELL MATURATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EDEMA; ENZYME REGULATION; ERYTHROPOIESIS; FIBROBLAST; GROWTH INHIBITION; HELPER CELL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HYPOTENSION; HYPOVOLEMIA; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MAXIMUM TOLERATED DOSE; MELANOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL EDEMA; PROTEIN TARGETING; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 8844238388     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.09.845410     Document Type: Review

References (18)

1. Coutts, S.J., Kelly, T.A., Snow, R.J. et al. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chem 1996, 39: 2087-94.
2. Snow, R., Kelly, T.A., Adams, J., Coutts, S., Perry, C. (Boehringer Ingelheim Pharmaceuticals Inc.). Method for making a prolineboronate ester. CA 2123128, EP 0641347, JP 1995501078, WO 9310127.
3. Kelly, T.A., Fuchs, V.U., Perry, C.W., Snow, R.J. The efficient synthesis and simple resolution of a prolineboronate ester suitable for enzyme-inhibition studies. Tetrahedron 1993, 49: 1009-16.
4. Gibson, F.S., Singh, A.K., Soumeillant, M.C., Manchand, P.S., Humora, M., Kronenthal, D.R. A practical synthesis of L-valylpyrrolidine-(2R)-boronic acid: Efficient recycling of the costly chiral auxiliary (+)-pinanediol. Org Process Res Dev 2002, 6: 814-6.
5. Snow, R.J., Bachovchin, W.W., Barton, R.W. et al. Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: Identification of a cyclic species containing a B-N bond. J Am Chem Soc 1994, 116: 10860-9.
6. Coutts, S.J., Adams, J., Krolikowski, D., Snow, R.J. Two efficient methods for the cleavage of pinanediol boronate esters yielding the free boronic acids. Tetrahedron Lett 1994, 35: 5109-12.
7. Ogawa, M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993, 81: 2844-53.
8. Whetton, A.D., Spooncer, E. Role of cytokines and extracellular matrix in the regulation of haemopoietic stem cells. Curr Opin Cell Biol 1998, 10: 721-6.
9. Demuth, H.-U., Heins, J. Catalytic mechanism of dipeptidyl peptidase IV. In: Dipeptidyl Peptidase IV (CD26) in Metabolism and Immune Response, B. Fleischer (Ed.), R.G. Landes Co., Austin, 1995, 1-34.
10. De Meester, I., Korom, S., Van Damme, J., Scharpe, S. CD26, let it cut or cut it down. Immunol Today 1999, 20: 367-75.
11. Jones, B., Adams, S., Miller, G.T., Jesson, M.I., Watanabe, T., Wallner, B.P. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 2003, 102: 1641-8.
12. Jones, B., Miller, G.T., Jesson, M.I., Watanabe, T., Wallner, B.P., Adams, S. Dipeptidyl peptidase inhibitor PT-100: An antitumor small molecule that amplifies immunity. Proc Am Soc Clin Oncol 2003, 22: Abst 860.
13. Adams, S., Jones, B. Enhanced anti-tumor activity of dipeptidyl peptidase inhibitor PT-100 in combination with chemotherapy in mice. Proc Am Ass Cancer Res 2004, 45: Abst 3820.
14. Adams, S., Miller, G.T., Jones, B. Dipeptidyl peptidase inhibitor PT-100 suppresses tumor growth in vivo and enhances chemotherapy in mice. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C109.
15. Adams, S., Miller, G.T., Jesson, M.I., Watanabe, T., Jones, B., Wallner, B.P. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 2004, 64: 5471-80.
16. Point's boroproline compound shows peptide adjuvant activity. DailyDrugNews.com (Daily Essentials) May 3, 2004.
17. Nemunaitis, J.J., Cunningham, C.C., Senzer, N.N., Haltom, E., Jones, B., Vukelja, S.J., Richards, D.A., Uprichard, M.J. A phase 1 trial of PT-100 in patients receiving myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 2004, 23: Abst 2572.
18. Point Therapeutics commences last planned phase II studies for talabostat. DailyDrugNews.com (Daily Essentials) July 5, 2004.